Blepharitis - Pipeline Review, H1 2018

  • ID: 4473101
  • Drug Pipelines
  • 58 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Kala Pharmaceuticals Inc
  • Merck & Co Inc
  • NicOx SA
  • MORE
Blepharitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2018, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Kala Pharmaceuticals Inc
  • Merck & Co Inc
  • NicOx SA
  • MORE
Introduction

Report Coverage

Blepharitis - Overview

Blepharitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Blepharitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Blepharitis - Companies Involved in Therapeutics Development

Allergan Plc

Hovione FarmaCiencia SA

InSite Vision Inc

Kala Pharmaceuticals Inc

Marinomed Biotechnologie GmbH

Merck & Co Inc

NicOx SA

Novaliq GmbH

Quorum Innovations LLC

Blepharitis - Drug Profiles

(doxycycline + omega 3 fatty acid) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-195263 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

azithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISV-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

loteprednol etabonate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-402 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Blepharitis and Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetracycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Blepharitis - Dormant Projects

Blepharitis - Product Development Milestones

Featured News & Press Releases

Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis

Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults

Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Blepharitis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Blepharitis - Pipeline by Allergan Plc, H1 2018

Blepharitis - Pipeline by Hovione FarmaCiencia SA, H1 2018

Blepharitis - Pipeline by InSite Vision Inc, H1 2018

Blepharitis - Pipeline by Kala Pharmaceuticals Inc, H1 2018

Blepharitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2018

Blepharitis - Pipeline by Merck & Co Inc, H1 2018

Blepharitis - Pipeline by NicOx SA, H1 2018

Blepharitis - Pipeline by Novaliq GmbH, H1 2018

Blepharitis - Pipeline by Quorum Innovations LLC, H1 2018

Blepharitis - Dormant Projects, H1 2018

List of Figures:

Number of Products under Development for Blepharitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Hovione FarmaCiencia SA
  • InSite Vision Inc
  • Kala Pharmaceuticals Inc
  • Marinomed Biotechnologie GmbH
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Quorum Innovations LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll